ARTICLE | Clinical News
CHMP recommends label update to AZ's Bydureon
December 1, 2017 9:52 PM UTC
EMA's CHMP recommended expanding the label of Bydureon exenatide from AstraZeneca plc (LSE:AZN; NYSE:AZN) to include treatment of Type II diabetes in combination with other glucose lowering treatment...
BCIQ Company Profiles
BCIQ Target Profiles